A Phase 2, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer
This study is testing a drug called dostarlimab for a specific type of rectal cancer that has not been treated yet. The main goal is to see if this treatment works so well that patients can avoid standard treatments like chemotherapy, radiation, and surgery.
This study is no longer enrolling new participants. It enrolled adults with stage II or III rectal cancer that had not been treated yet (no earlier radiation, chemotherapy or surgery for it) and had not spread to distant parts of the body. Their tumors had to test dMMR (mismatch repair deficient) or MSI-H (microsatellite instability-high), features found in about 3 in 100 locally advanced rectal cancers. People with an active autoimmune disease treated in the past 2 years, a history of lung inflammation (pneumonitis or interstitial lung disease), or severe immune side effects from earlier immunotherapy could not take part.
Participants will receive dostarlimab, an immunotherapy medicine that helps your immune system fight the cancer. If the treatment makes the cancer completely disappear, you will be closely monitored with regular check-ups instead of having surgery.
The study is running at 42 sites in 10 countries: 7 in the United States (Los Angeles, Albuquerque, New York, Pittsburgh, Nashville, Dallas and Richmond), 4 in Canada (Ottawa, Toronto, Montreal and Sherbrooke), and others in Spain, France, Germany, Japan, South Korea, Italy, the United Kingdom and the Netherlands. It is still active but no longer enrolling new participants. Based on early results from this study, the FDA granted accelerated approval to dostarlimab (Jemperli) on October 19, 2026 for adults with stage II or III dMMR/MSI-H locally advanced rectal cancer. Continued approval may depend on further results.
- 1Tests dostarlimab immunotherapy as a standalone treatment for rectal cancer
- 2Aims to help patients safely avoid chemotherapy, radiation, and surgery
- 3Currently active but not open for new participants
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.